 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8889909192939495969798...100101» |
- New trial: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) - Sep 2, 2015
P0, N=60, Not yet recruiting, Sponsor: Andrew Brenner
- | Phase classification, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 27, 2015
P2, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P4 --> P2
- Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: PARSIFAL: Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Aug 27, 2015
P2, N=304, Recruiting, Sponsor: Medica Scientia Innovation Research
Phase classification: P4 --> P2 Not yet recruiting --> Recruiting
- Trial initiation date, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Aug 26, 2015
P2, N=59, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting Initiation date: Aug 2014 --> Aug 2015
- letrozole / Generic mfg.
Trial completion, Enrollment change: Letrozole for Lymphangioleiomyomatosis (clinicaltrials.gov) - Aug 26, 2015
P2, N=17, Completed, Sponsor: University of Cincinnati
Initiation date: Aug 2014 --> Aug 2015 Recruiting --> Completed | N=60 --> 17
- | letrozole / Generic mfg., zoledronic acid / Generic mfg.
Phase classification, Surgery: FEMZONE: Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer (clinicaltrials.gov) - Aug 24, 2015
P4, N=168, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=60 --> 17 Phase classification: P2/3 --> P4
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Aug 21, 2015
P2, N=160, Recruiting, Sponsor: Japan Breast Cancer Research Group
Phase classification: P2/3 --> P4 Trial primary completion date: Mar 2017 --> Jun 2017
- || Herceptin (trastuzumab) / Roche
Trial primary completion date: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Aug 21, 2015
P2, N=150, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: Oct 2015 --> Jun 2016
- letrozole / Generic mfg.
Trial primary completion date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Aug 14, 2015
P2, N=115, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Jun 2015 --> Jun 2020
- Piqray (alpelisib) / Novartis
Trial primary completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Jun 2015 --> Jun 2020 Trial primary completion date: Oct 2015 --> Oct 2017
- |||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial primary completion date: MA.17R: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy (clinicaltrials.gov) - Aug 13, 2015
P3, N=1918, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Jul 2015 --> Jul 2017
- Farydak (panobinostat) / Secura Bio
Enrollment closed, Trial primary completion date, Metastases: Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 12, 2015
P1/2, N=48, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2015 --> Jul 2017 Suspended --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Jul 2016
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer (clinicaltrials.gov) - Aug 12, 2015
P3, N=177, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Suspended --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Jul 2016 Recruiting --> Completed
- | carotuximab IV (ENV-105) / Kairos Pharma
New P1/2 trial, Metastases: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) - Aug 11, 2015
P1/2, N=35, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- ||||||| letrozole / Generic mfg.
Trial completion, Metastases: Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2015
P3, N=865, Completed, Sponsor: Intarcia Therapeutics
Recruiting --> Completed No longer recruiting --> Completed
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion: Ovulation Induction in Clomiphene Citrate Resistant PCO Women (clinicaltrials.gov) - Aug 1, 2015
P0, N=100, Completed, Sponsor: Cairo University
No longer recruiting --> Completed Recruiting --> Completed
- || everolimus / Generic mfg.
New P3 trial, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jul 30, 2015
P3, N=253, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Surgery: Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Jul 17, 2015
P3, N=610, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Trial primary completion date: Dec 2012 --> Aug 2012
- letrozole / Generic mfg.
Enrollment open: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Jul 17, 2015
P4, N=20, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Enrollment open, Trial primary completion date, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=30, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - Jul 16, 2015
P2, N=160, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- | Ibrance (palbociclib) / Pfizer
New P1 trial, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Jul 15, 2015
P1, N=25, Not yet recruiting, Sponsor: Pfizer
- letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Jul 14, 2015
P2, N=72, Recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | letrozole / Generic mfg., tamoxifen / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer (clinicaltrials.gov) - Jul 13, 2015
P3, N=558, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Herceptin (trastuzumab) / Roche
Trial initiation date: HERAKLES: Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women (clinicaltrials.gov) - Jul 10, 2015
P2, N=132, Recruiting, Sponsor: Gangnam Severance Hospital
Active, not recruiting --> Completed Initiation date: Oct 2014 --> Mar 2015
- || letrozole / Generic mfg.
New P3 trial: PCOSAPct: The Clinical Trial of Acupuncture Pre-treatment on PCOS (clinicaltrials.gov) - Jul 8, 2015
P3, N=240, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Metastases: PARSIFAL: Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jul 8, 2015
P2, N=304, Not yet recruiting, Sponsor: Medica Scientia Innovation Research
- taselisib (GDC-0032) / Roche
Enrollment change, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Jul 2, 2015
P1/2, N=724, Recruiting, Sponsor: Genentech, Inc.
Initiation date: Oct 2014 --> Mar 2015 N=392 --> 724
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Jun 29, 2015
P2, N=58, Active, not recruiting, Sponsor: Pfizer
N=392 --> 724 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Biomarker, New P2 trial: TGOG1005: A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix (clinicaltrials.gov) - Jun 26, 2015
P2, N=44, Recruiting, Sponsor: Buddhist Tzu Chi General Hospital
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Enrollment change, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Jun 26, 2015
P1, N=97, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=63 --> 97
- letrozole / Generic mfg.
Enrollment change: Cost-Less: Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? (clinicaltrials.gov) - Jun 25, 2015
P4, N=0, Withdrawn, Sponsor: Center for Human Reproduction
Recruiting --> Active, not recruiting | N=63 --> 97 N=250 --> 0
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion, Enrollment change: Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=392, Completed, Sponsor: Novartis Pharmaceuticals
N=250 --> 0 Active, not recruiting --> Completed | N=610 --> 392
- ||| fexagratinib (ABSK091) / Abbisko
Phase classification, Enrollment change, Trial primary completion date, Combination therapy: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (clinicaltrials.gov) - Jun 23, 2015
P2a, N=56, Recruiting, Sponsor: Imperial College London
Active, not recruiting --> Completed | N=610 --> 392 Phase classification: P1/2 --> P2a | N=99 --> 56 | Trial primary completion date: Mar 2013 --> Mar 2016
- letrozole / Generic mfg.
New P4 trial: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Jun 12, 2015
P4, N=20, Not yet recruiting, Sponsor: University of California, San Francisco
- letrozole / Generic mfg.
Trial primary completion date: HEPAROB: Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men (clinicaltrials.gov) - Jun 11, 2015
P4, N=30, Recruiting, Sponsor: University Hospital, Ghent
Phase classification: P1/2 --> P2a | N=99 --> 56 | Trial primary completion date: Mar 2013 --> Mar 2016 Trial primary completion date: Mar 2015 --> Sep 2015
- letrozole / Generic mfg.
Trial primary completion date: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Oct 2015 --> Oct 2016
- letrozole / Generic mfg.
Trial termination: Randomized Study of Letrozole and Trilostane for Medical Abortion (clinicaltrials.gov) - Jun 11, 2015
P2, N=36, Terminated, Sponsor: Kristina Gemzell Danielsson
Recruiting --> Terminated; No access to study drug Trilostan. Company closed down
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change, Combination therapy: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=160, Recruiting, Sponsor: Dana-Farber Cancer Institute
Company closed down N=120 --> 160
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=120 --> 160 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- letrozole / Generic mfg.
New P2 trial, IO biomarker: The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues (clinicaltrials.gov) - May 29, 2015
P2, N=20, Completed, Sponsor: The University of Hong Kong
- | letrozole / Generic mfg.
New P2 trial: COAT: Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy (clinicaltrials.gov) - May 27, 2015
P2, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment closed, Enrollment change: Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4) (clinicaltrials.gov) - May 26, 2015
P3, N=2056, Active, not recruiting, Sponsor: National Institute for Cancer Research, Italy
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Recruiting --> Active, not recruiting | N=4050 --> 2056
- letrozole / Generic mfg., everolimus / Generic mfg.
New trial, Metastases: Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls (clinicaltrials.gov) - May 21, 2015
P=N/A, N=50, Recruiting, Sponsor: Sinai Hospital of Baltimore
- Elonva (corifollitropin alfa) / Organon
New P1 trial: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study (clinicaltrials.gov) - May 19, 2015
P1, N=40, Enrolling by invitation, Sponsor: University of Sao Paulo
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open: Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=20, Recruiting, Sponsor: Sinai Hospital of Baltimore
Recruiting --> Active, not recruiting | N=4050 --> 2056 Not yet recruiting --> Recruiting
- ||||||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women (clinicaltrials.gov) - May 19, 2015
P3, N=378, Completed, Sponsor: Spanish Breast Cancer Research Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013
- |||| letrozole / Generic mfg., dasatinib / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (clinicaltrials.gov) - May 7, 2015
P2, N=108, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014
- || everolimus / Generic mfg.
Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - May 1, 2015
P2, N=70, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014 Trial primary completion date: Nov 2016 --> Feb 2017
- | letrozole / Generic mfg.
New P2 trial: Letrozole in Assisted Reproductive Technology (clinicaltrials.gov) - Apr 29, 2015
P2, N=80, Recruiting, Sponsor: Assiut University